- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02735863
ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase IIa Trial to Compare the Safety of ABX464 Given at a Fixed Dose to Placebo in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment (Darunavir/Ritonavir or Darunavir/Cobicistat).
Study Overview
Detailed Description
This study is a placebo-controlled study aimed at assessing the safety of ABX464 administered at 50 mg o.d. and 150 mg versus placebo in HIV infected patients who are treated with darunavir + ritonavir (DRV/RTV) or darunavir + cobicistat (DRV/COBI). Eligible patients should be treated with darunavir + ritonavir or darunavir + cobicistat as monotherapy for at least 8 weeks prior to baseline. Patients should be fully suppressed (< 50 copies/mL) at least during the last 6 months prior to enrolment.
Upon screening visit, eligible patients will continue DRV/RTV or DRV/COBI single regimen given respectively at 800 mg of darunavir with 100 mg of ritonavir or 150 mg of cobicistat once a day with food in the morning.
At Day 0, study drug (ABX464 or its matching placebo) will be added on top of this background therapy for the next 28 days. ABX464 or its matching placebo will be given once a day at 50 mg or 150 mg.
At day 29, DRV/RTV or DRV/COBI and ABX464 or its matching placebo (i.e. all treatments) will be stopped. The viral load will be monitored twice a week during the first three weeks and weekly during the next weeks. In case of Viral Rebound (VR; defined below), ART will be resumed.
A 3:1 randomization ratio will be applied meaning that, per treatment block, 3 patients will receive ABX464 on top of DRV/RTV or DRV/COBI and 1 patient will receive placebo on top of DRV/RTV or DRV/COBI.
Dose limiting toxicity (DLT) is defined as a grade 3 or higher adverse event as defined by the "Division of AIDS table for grading the severity of adult and pediatric adverse events" (including signs/symptoms, lab toxicities and/or clinical events) considered by the Data Safety Monitoring Board as probably or definitely related to study treatment.
If more than 2 DLTs occur during the treatment period of the first four treated patients, then the enrolment of additional patients will be stopped. In addition, in case of a life threatening (grade 4) adverse reaction enrolment and treatment of ongoing patients will be immediately discontinued. In both cases, enrolment will only be resumed upon the decision of the sponsor if the Data Safety Monitoring Board can conclude that the causality of the event was unrelated or unlikely related to study treatment.
Thorough pharmacokinetics analysis will be performed to characterize potential drug-drug interactions between ABX464 and DRV/RTV-COBI.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Bruxelles, Belgium, 1000
- C.H.U. Saint-Pierre
-
Ghent, Belgium, 9000
- Ghent University Hospital
-
Liège, Belgium, 4000
- CHU Sart Tilman
-
-
-
-
-
Montpellier, France, 34 295
- CHU de Montpellier - Hôpital Gui de Chauliac
-
-
-
-
-
Barcelona, Spain, 08036
- Hospital Clínic
-
Barcelona, Spain, 08916
- Hospital Universitari Germans Trias i Pujo
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients infected with HIV;
- Patients with HIV plasma viral load ≤ 50 copies mL-1 during the 6 months prior to screening with a maximum of 2 blips during this period;
- Patients treated by DRV/RTV or DRV/COBI as a monotherapy for at least 8 weeks prior to baseline;
- Patients' HIV plasma viral load ≤100,000 copies mL-1 at any time (apart from primary infection if recorded);
- Patients' CD4+ T cells count ≥ 250 cells per mm3 at any time since diagnosis;
- Patients with CD4+ T cells count ≥ 600 cells per mm3 at screening;
- Man or woman aged 18-65 years;
Exclusion Criteria:
- Patient displaying any HIV protease inhibitor resistance mutation as listed in the current version of the HIV drug resistance database (Stanford University);
- Patient having had previously a viral load ≥ 500 copies mL-1 confirmed by a second measure since the initiation of the current ART;
- History of an AIDS-defining clinical illness;
- Concomitant AIDS-related opportunistic infection;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ABX464
Fixed dose of ABX464 50mg once daily given during 28 days in association with darunavir + ritonavir (DRV/RTV) or darunavir + cobicistat (DRV/COBI)
|
50 mg or 150mg once daily for 28 days
|
Placebo Comparator: ABX464 Matching placebo
Matching placebo of ABX464 given at 50mg once daily in association with darunavir + ritonavir (DRV/RTV) or darunavir + cobicistat (DRV/COBI)
|
ABX464 matching placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Frequency of Adverse Reactions graded according to the "Division of AIDS table for grading the severity of adult and pediatric adverse events" (Version 2.0 November 2014)
Time Frame: Up to 4 months
|
Up to 4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Viral Rebound
Time Frame: Up to 3 months
|
Time To Viral Rebound is defined as the time between treatment stop (i.e.
day 29) and viral rebound detection
|
Up to 3 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ABX464-004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infection
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Beckman Coulter, Inc.CompletedHIV I Infection | HIV-2 InfectionFrance
-
Allegheny Singer Research Institute (also known...Active, not recruitingHIV Infections | HIV-1-infection | HIV I InfectionUnited States
-
Rockefeller UniversityCompletedHIV Infection | Healthy Volunteers | HIV-1 InfectionUnited States
-
Erasmus Medical CenterRecruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
Erasmus Medical CenterActive, not recruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
AIDS Healthcare FoundationUniversity of California, Los AngelesCompleted
-
Merck Sharp & Dohme LLCCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedHIV-1 Infection | HIV Antibodies | Neutralizing Antibody | Viral Load | Monoclonal AntibodyUnited States
Clinical Trials on ABX464
-
Abivax S.A.CompletedRheumatoid ArthritisBelgium, France, Czechia, Hungary, Poland
-
Abivax S.A.TerminatedCOVID-19Spain, Belgium, United Kingdom, Germany, France, Brazil, Italy, Mexico
-
Abivax S.A.CompletedHIV Infections | Health VolunteersSpain
-
Abivax S.A.CompletedHuman Immunodeficiency Virus InfectionsThailand, Mauritius
-
Abivax S.A.Completed
-
Abivax S.A.RecruitingUlcerative ColitisUnited States, Belgium, Korea, Republic of, Australia, Austria, Italy, China, Netherlands, Spain, Turkey, United Kingdom, Canada, France, Greece, Germany, Switzerland, India, Portugal, Poland, Hungary, Bulgaria, Argentina, Czechia
-
Abivax S.A.RecruitingUlcerative ColitisUnited States, Spain, Italy, Bosnia and Herzegovina, Croatia, Israel, Japan, Mexico, Romania, Belgium, New Zealand, Hungary, India, Ireland, Serbia, France, Poland, Canada, United Kingdom, Czechia, Germany, Argentina, Bulgaria, Brazil, ... and more
-
Abivax S.A.Active, not recruitingUlcerative ColitisBelgium, Poland, Czechia, Hungary
-
Abivax S.A.Orion Corporation, Orion PharmaActive, not recruitingUlcerative ColitisBelgium
-
Abivax S.A.Active, not recruitingUlcerative ColitisPoland, Spain, France, Germany, Italy, Slovenia, Belgium, Canada, Belarus, Hungary, Czechia, Austria, United Kingdom, Serbia, Slovakia, Ukraine